Net profit of the year

Impairment of the cell therapy activities

Increase in provisions

Adjustment for other non-cash transactions

Adjustment for items to disclose separately under operating cash flow

Adjustment for items to disclose under investing and financing cash flows

Change in working capital other than deferred income

Cash used for other liabilities related to the disposal of subsidiaries

Cash used for other liabilities related to the acquisition of subsidiaries

Decrease in deferred income

Cash used in operations

Interest paid

Interest received

Corporate taxes paid (-)/received

Net cash flow used in operating activities

Purchase of property, plant and equipment

Purchase of intangible fixed assets

Proceeds from disposal of property, plant and equipment

Purchase of financial investments

Investment income received related to financial investments

Sale of financial investments

Proceeds from settlement of hedging instrument

Cash in/cash out (-) from the disposal of subsidiaries, net of cash disposed of

Convertible loan issued to third party

Acquisition of equity investments held at fair value through other comprehensive income

Net cash flow generated from investing activities

Payment of lease liabilities

Net cash flow used in financing activities

Increase/decrease (-) in cash and cash equivalents

Increase/decrease (-) in cash and cash equivalents

Effect of exchange rate differences on cash and cash equivalents

Cash and cash equivalents at end of the year